OTCMKTS:AZNCF AstraZeneca (AZNCF) Stock Forecast, Price & News $144.55 -0.71 (-0.49%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$144.55▼$144.5850-Day Range$133.12▼$153.1052-Week Range$104.50▼$153.10Volume649 shsAverage Volume3,719 shsMarket CapitalizationN/AP/E Ratio177.14Dividend Yield1.94%Price TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort Interest AstraZeneca MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestBearishDividend StrengthWeakBased on Four FactorsSustainabilityN/ANews Sentiment0.25Based on 10 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.05 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for AstraZeneca. Previous Next 2.0 Short Interest Percentage of Shares ShortedShort Interest Ratio / Days to CoverAstraZeneca has a short interest ratio ("days to cover") of 23.7, which indicates bearish sentiment.Change versus previous monthShort interest in AstraZeneca has recently decreased by 81.19%, indicating that investor sentiment is improving significantly. Previous Next 1.7 Dividend Strength Dividend LeadershipAstraZeneca is a leading dividend payer. It pays a dividend yield of 3.89%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthAstraZeneca does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of AstraZeneca is 343.14%. Payout ratios above 75% are not desirable because they may not be sustainable. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AZNCF. Previous Next 1.8 News and Social Media Coverage News SentimentAstraZeneca has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.11 average news sentiment score of Health Technology companies.News Coverage This WeekMarketBeat has tracked 10 news articles for AstraZeneca this week, compared to 11 articles on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AstraZeneca insiders have not sold or bought any company stock.Percentage Held by Institutions40.87% of the stock of AstraZeneca is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of AstraZeneca is 177.14, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 134.71.Price to Earnings Ratio vs. SectorThe P/E ratio of AstraZeneca is 177.14, which means that it is trading at a more expensive P/E ratio than the Health Technology sector average P/E ratio of about 14.80. Previous Next See Top Rated MarketRank™ Stocks Here About AstraZeneca (OTCMKTS:AZNCF) StockAstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.Read More Receive AZNCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter. Email Address AZNCF Stock News HeadlinesMay 27, 2023 | msn.comAstraZeneca aids government in fight vs kidney diseaseMay 26, 2023 | finance.yahoo.comAstraZeneca PLC: Reaffirming BUY; strong product pipelineMay 27, 2023 | Behind the Markets (Ad)"Chilling War Games Show US Forces Crushed" – FOX NEWS=== BREAKING === "Chilling War Games Show US Forces Crushed" - FOX NEWS After losing to China in repeated war games, U.S. military to spend billions on new "living missile" for armed forces. Investors stand to reap 35,960% on shares of small defense contractor that makes powerful new weapon. Get the name of the stock here >>>May 26, 2023 | lse.co.ukTOP NEWS: AstraZeneca's Ultomiris wins another approval in JapanMay 26, 2023 | msn.comAstraZeneca announces good results from endometrial cancer trialMay 26, 2023 | lse.co.ukAstraZeneca's Imfinzi plus Lynparza effective for endometrial cancerMay 26, 2023 | markets.businessinsider.comAstraZeneca Reports Positive Results From DUO-E Phase III Trial - Quick FactsMay 25, 2023 | msn.comAstraZeneca: Think Medium-To-Long TermMay 27, 2023 | Behind the Markets (Ad)"Chilling War Games Show US Forces Crushed" – FOX NEWS=== BREAKING === "Chilling War Games Show US Forces Crushed" - FOX NEWS After losing to China in repeated war games, U.S. military to spend billions on new "living missile" for armed forces. Investors stand to reap 35,960% on shares of small defense contractor that makes powerful new weapon. Get the name of the stock here >>>May 25, 2023 | businesswire.comAstraZeneca will highlight momentum of practice-changing cancer medicines across its robust pipeline at ASCO 2023May 22, 2023 | msn.com1 world-beating FTSE 100 share I’d buy today and it’s not AstraZeneca or National GridMay 21, 2023 | msn.comWeek In Review: LaNova Sells Pre-Clinical ADC To AstraZeneca In $600 Million DealMay 19, 2023 | news.yahoo.comAn AstraZeneca executive said the quiet part about China out loudMay 19, 2023 | msn.comUPDATE 1-AstraZeneca will seek to "love the Communist Party" - China bossMay 19, 2023 | msn.comAstraZeneca will seek to "love the Communist Party", its China boss saysMay 17, 2023 | marketwatch.comAstraZeneca Tagrisso Drug In Combination With Chemo Showed Strong Improvement In TrialMay 17, 2023 | americanbankingnews.comAstraZeneca PLC (OTCMKTS:AZNCF) Short Interest Down 9.5% in AprilMay 16, 2023 | msn.comAstraZeneca to leave leading U.S. drug lobby groupMay 14, 2023 | thetimes.co.ukCreditors ‘lose out’ in battle over former AstraZeneca siteMay 12, 2023 | ft.comDirectors’ Deals: AstraZeneca chair bets on upward momentumMay 9, 2023 | marketwatch.comAstraZeneca PLC ADR falls Tuesday, still outperforms marketMay 9, 2023 | benzinga.comWhat Does AstraZeneca's Debt Look Like?May 9, 2023 | marketwatch.comAstraZeneca outperforms market despite losses on the dayMay 8, 2023 | marketwatch.comAstraZeneca PLC ADR rises Monday, still underperforms marketMay 5, 2023 | marketwatch.comAstraZeneca rises Friday, still underperforms marketMay 5, 2023 | marketwatch.comAstraZeneca PLC ADR falls Thursday, still outperforms marketMay 5, 2023 | msn.comAI vs. cancer: AstraZeneca exec reveals how COVID pandemic helped develop early cancer diagnosis techSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AZNCF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceuticals: Major Sub-IndustryN/A SectorHealth Technology Current SymbolOTCMKTS:AZNCF CUSIPN/A CIK901832 WebN/A Phone442037495000FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio177.14 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Key ExecutivesPascal SoriotChief Executive Officer & Executive DirectorPam P. ChengExecutive VP-Operations & Information TechnologyAradhana SarinChief Financial Officer & Executive DirectorMenelas NICOLAS PangalosEVP-Biopharmaceuticals Research & DevelopmentCindy L. HootsChief Digital & Information OfficerKey CompetitorsGenomma Lab InternacionalOTCMKTS:GNMLFMindset PharmaOTCMKTS:MSSTFCanSino BiologicsOTCMKTS:CASBFCellaVision AB (publ)OTCMKTS:CLVSFMedigeneOTCMKTS:MDGEFView All CompetitorsInstitutional OwnershipBoston Common Asset Management LLCBought 271,130 shares on 5/17/2023Ownership: 0.000%Vigilant Capital Management LLCSold 125 shares on 5/1/2023Ownership: 0.000%View All Institutional Transactions AZNCF Stock - Frequently Asked Questions Should I buy or sell AstraZeneca stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AZNCF shares. View AZNCF analyst ratings or view top-rated stocks. How have AZNCF shares performed in 2023? AstraZeneca's stock was trading at $139.28 at the start of the year. Since then, AZNCF stock has increased by 3.8% and is now trading at $144.55. View the best growth stocks for 2023 here. Are investors shorting AstraZeneca? AstraZeneca saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 502,800 shares, a drop of 9.5% from the April 15th total of 555,700 shares. Based on an average daily volume of 21,500 shares, the short-interest ratio is presently 23.4 days. View AstraZeneca's Short Interest. Is AstraZeneca a good dividend stock? AstraZeneca (OTCMKTS:AZNCF) pays an annual dividend of $2.80 per share and currently has a dividend yield of 3.89%. The dividend payout ratio is 343.14%. Payout ratios above 75% are not desirable because they may not be sustainable. What is AstraZeneca's stock symbol? AstraZeneca trades on the OTCMKTS under the ticker symbol "AZNCF." Who are AstraZeneca's major shareholders? AstraZeneca's stock is owned by a number of retail and institutional investors. Top institutional investors include Boston Common Asset Management LLC (0.00%) and Vigilant Capital Management LLC (0.00%). How do I buy shares of AstraZeneca? Shares of AZNCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is AstraZeneca's stock price today? One share of AZNCF stock can currently be purchased for approximately $144.55. How can I contact AstraZeneca? The company can be reached via phone at 442037495000. This page (OTCMKTS:AZNCF) was last updated on 5/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AstraZeneca PLC Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.